UNITED STATES
SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 |
FORM
8-K
|
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
Date
of
Report (Date of earliest event reported): June 4,
2007
|
ACCESS
PHARMACEUTICALS, INC.
|
|
(Exact
name of registrant as specified in its charter)
|
Delaware
|
0-9314
|
83-0221517
|
|
|
|
(State
or other jurisdiction
of incorporation) |
(Commission
File Number) |
(IRS
Employer
Identification No.) |
2600
Stemmons Freeway, Suite 176
Dallas, Texas |
|
75207
|
|
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant's telephone number, including
area code:
|
(214)
905-5100
|
|
|
|
|
|
|
(Former
name or former address, if changed since last report)
|
Check the appropriate box below if
the
Form 8-K filing is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions
(see
General Instruction A.2. below):
|
/x/
|
Written communications pursuant to
Rule
425 under the Securities Act (17 CFR 230.425)
|
/ /
|
Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
/ /
|
Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
/ /
|
Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
SIGNATURES
|
|
|
ACCESS PHARMACEUTICALS, INC.
|
|
|
|
By:
|
/s/ Stephen B. Thompson
|
|
|
|
|
|
|
Stephen B. Thompson
|
|
|
Vice President, Chief Financial
Officer
|
|
|